Arguably, baricitinib should disrupt ACE2-mediated SARS-CoV-2 endocytosis entry into cells within the same therapeutic plasma concentration range when used for rheumatoid arthritis, and therefore baricitinib is postulated to be another candidate for clinical trials to treat COVID-19 (41, 42). This evidence concerns the gene ACE2 and COVID-19.